Vuity eye drops available for presbyopia treatment


December 09, 2021

1 min read

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected].

Vuity, eye drops for the treatment of presbyopia, are now available, according to a press release from AbbVie.

“We are delighted to be able to bring this unique treatment to market sooner than expected for the millions of presbyopic Americans who could benefit from it.” Jag Dosanjh, The senior vice president of medical therapeutics at Allergan, an AbbVie company, said in the statement.

Vuity provides a formulation of pilocarpine to the eye to reduce pupil size, improving near and intermediate vision without sacrificing distance vision.

The FDA approved Vuity in October following positive results from the pivotal Phase 3 clinical studies GEMINI 1 and GEMINI 2 that evaluated the efficacy, safety and tolerability of Vuity for presbyopia. Both studies met their primary endpoints with a significant proportion of Vuity-treated patients gaining three or more lines in high contrast-corrected near-mesopic high contrast visual acuity without losing more than one line of distance-corrected visual acuity. day 30, hour 3, compared to placebo.

The once-daily treatment is the first FDA-approved eye drops for presbyopia.


Comments are closed.